SUPPLEMENTARY MATERIAL

On the Mechanism of Berberine-INF55 (5-Nitro-2-Phenylindole) Hybrid Antibacterials


A School of Chemistry, University of Wollongong, Wollongong, NSW 2522, Australia.
B Department of Biology and Antimicrobial Discovery Center, Northeastern University, Boston, MA 02115, USA.
C Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
D Department of Medicine, Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
E Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
F These authors contributed equally to this work.

Corresponding author. Email: mkelso@uow.edu.au
Table of Contents

Figure S1. $^1$H NMR spectrum of 8.

Figure S2. $^{13}$C (APT) NMR spectrum of 8.

Figure S3. $^1$H NMR spectrum of 9.

Figure S4. $^{13}$C (APT) NMR spectrum of 9.

Figure S5. $^1$H NMR spectrum of 19.

Figure S6. $^{13}$C (APT) NMR spectrum of 19.

Figure S7. $^1$H NMR spectrum of 20.

Figure S8. $^{13}$C (APT) NMR spectrum of 20.
Figure S1. $^1$H NMR spectrum of 8.

Figure S2. $^{13}$C (APT) NMR spectrum of 8.
Figure S3. $^1$H NMR spectrum of 9.

Figure S4. $^{13}$C (APT) NMR spectrum of 9.
Figure S5. $^1$H NMR spectrum of 19.

Figure S6. $^{13}$C (APT) NMR spectrum of 19.
Figure S7. $^1$H NMR spectrum of 20.

Figure S8. $^{13}$C (APT) NMR spectrum of 20.